Chronic Myelogenous Leukemia in chronic phase (CML-CP) research hub

A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

This study looks at new treatments for a type of blood cancer called Chronic Myeloid Leukaemia (CML). It compares a new drug, asciminib (Scemblix), with existing treatments (imatinib or nilotinib) in people whose CML hasn't fully responded to imatinib yet. The main goal is to see which treatment helps more people achieve a very low level of cancer cells.